FIGURE 2.

(A) Switching patterns of RD patients with median time (IQR) until switch. TNFα inhibitors (etanercept, infliximab, adalimumab, certolizumab, golimumab) were colored purple, selective immunosuppressants (abatacept, tofacitinib, baricitinib) were colored red, interleukin inhibitors (anakinra, ustekinumab, tocilizumab, secukinumab) were colored green and rituximab was colored yellow. (B) Switching patterns of IBD patients with median time until switch. TNFα inhibitors (infliximab, adalimumab, golimumab) were colored purple, selective immunosuppressants (vedolizumab) were colored red and interleukin inhibitors (anakinra, ustekinumab) were colored green. (C) Switching patterns of psoriasis patients with median time until switch. TNFα inhibitors (etanercept, infliximab, adalimumab) were colored purple and interleukin inhibitors (ustekinumab, secukinumab) were colored green